Bright Minds Biosciences Net Cash Flow 2022-2024 | DRUG

Bright Minds Biosciences net cash flow from 2022 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.

Bright Minds Biosciences Net Cash Flow 2022-2024 | DRUG

Bright Minds Biosciences net cash flow from 2022 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$225.3B
Amgen (AMGN)$164.8B
Gilead Sciences (GILD)$144.5B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.4B
GSK (GSK)$77.5B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$42.9B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.7B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.7B
Biogen (BIIB)$19.3B
Illumina (ILMN)$17.3B
Genmab (GMAB)$15B
Genmab (GNMSF)$15B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.4B
QIAGEN (QGEN)$11.5B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.2B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8B
Roivant Sciences (ROIV)$7.9B